Annual Drug Patent Expirations for LYBALVI
Lybalvi is a drug marketed by Alkermes Inc and is included in one NDA. It is available from one supplier. There are twelve patents protecting this drug.
This drug has sixty-three patent family members in twenty-seven countries.
The generic ingredient in LYBALVI is olanzapine; samidorphan l-malate. One supplier is listed for this compound. Additional details are available on the olanzapine; samidorphan l-malate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
